Men could soon be offered quick MRI scans lasting under 15 minutes to detect prostate cancer earlier, under new recommendations from international experts.

Prostate cancer is one of the most common cancers among men. Many cases grow slowly and may never become life-threatening. Because of this, doctors often recommend a management approach called “active ...

"If he can't sit through a film or a long dinner without constantly shifting his weight, crossing and uncrossing his legs, or standing up to stretch, it may not just be restlessness. That sort of deep ...

Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a ...

During Kidney Cancer Awareness Month, Dr. Eric Singer shares warning signs, risk factors and when younger adults should speak with a doctor about kidney health. March is Kidney Cancer Awareness Month, ...

Data from Vista Health, a leading UK provider of private diagnostic services, has revealed the worrying knowledge gap when it comes to the prostate, as 26 percent of men do not know what their ...

Study found men with low testosterone levels were associated with a 60% higher likelihood that prostate cancer managed on active surveillance would progress to a more aggressive state over time ...

A group of doctors who specialize in cancer have detailed four subtle symptoms of the disease that people often overlook. The American Cancer Society predicts 2.1 million people in the US will be ...

What you need to know: Cervical cancer alone remains one of the most common cancers affecting Ugandan women, while breast cancer cases have steadily increased in recent years. The initiative, ...

Tony Collier, who was diagnosed with incurable prostate cancer in 2017, said: "If I'd had that simple blood test I could be in a totally different position now, instead of being given a worst case ...

Monte Rosa Therapeutics recently reported updated Phase 1/2 data showing that its investigational GSPT1 degrader MRT-2359, in combination with enzalutamide, was well-tolerated and produced positive ...